[at noodls] – LEXICON PHARMACEUTICALS TO PRESENT AT THE JEFFERIES 2012 GLOBAL HEALTHCARE CONFERENCE The Woodlands, Texas, November 12, 2012 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LX4211 Phase 2b Results Presented at American Heart Association Annual Conference LX4211 PHASE 2B RESULTS PRESENTED AT AMERICAN HEART ASSOCIATION ANNUAL CONFERENCE The Woodlands, Texas, November 6, 2012 … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results LEXICON PHARMACEUTICALS REPORTS ON CLINICAL PROGRAM STATUS AND 2012 THIRD QUARTER RESULTS Conference Call at 11:00 … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LEXICON TO PROVIDE THIRD QUARTER 2012 FINANCIAL RESULTS Conference Call and Webcast to Follow The Woodlands, Texas, October 31, 2012 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingDespite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ:LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company had more than $225M … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Lexicon Announces Proposed Common Stock Offering The Woodlands, Texas, October 17, 2012 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it commenced an offering to sell, subject to … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingTwo pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase II trial of telotristat … moreView todays social media effects on LXRXView the latest stocks trending across Twitter. Click to view dashboard […]
